
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International's Healthcare Systems & Technologies segment has demonstrated consistent sales growth, with increases of approximately 6% and 2% year-over-year in the first and second quarters of 2025, respectively, and projected growth of about 4% and 2% in the subsequent quarters. The company's strategic acquisition of Hillrom in late 2021 has enhanced its portfolio, enabling it to offer a broader array of medical equipment, which may further drive sales as the healthcare market adapts to evolving demands. Additionally, targeted pricing initiatives are expected to contribute positively to sales growth by approximately 100 basis points for both 2024 and 2025, bolstering Baxter's financial outlook.
Bears say
Baxter International's stock outlook is negatively impacted by a disappointing performance in the second quarter of 2025, with sales, margins, and earnings per share all falling below consensus expectations. This underperformance follows a period from 2021 to 2023 marked by operational missteps and inconsistent quarterly results, which have led to negative guidance revisions. Additionally, the company's gross margins of 40.7% and operating margins of 15.1% have both missed consensus estimates, primarily due to sales softness, manufacturing inefficiencies, and an unfavorable product mix.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares